Results 181 to 190 of about 252,158 (241)

Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma, Panagiota Tsitsi, Nirosen Vijiaratnam, Camila Aquino, Stephen R. Duma, Norbert Kovacs, Kigocha Lameck Okeng'o, Aparna Wagle Shukla, Roongroj Bhidayasiri, Tiago A. Mestre, Alvaro Sanchez Ferro, Alberto J. Espay, Michelle H.S. Tosin, Matej Skorvanek, Ioanna Markaki   +14 more
wiley   +1 more source

Increased Cerebrospinal Fluid Lactate Levels in Schizophrenia and Major Depressive Disorder: NCNP Biobank Study in Japan. [PDF]

Neuropsychopharmacol Rep
Hagihara H, Hattori K, Kunugi H, Miyakawa T.   +3 more
europepmc   +1 more source

Basal Forebrain Volume and Concurrent Hallucinations and Mild Cognitive Impairment in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visual hallucinations (VH) and mild cognitive impairment (MCI) often co‐occur in Parkinson's Disease (PD). Each symptom in isolation is associated with cholinergic basal forebrain (BF) atrophy. However, it is unclear whether BF integrity relates to one symptom preferentially or to their co‐occurrence, and whether this relationship ...
Sabrina M. Adamo, Vaishali Mutreja, Marta Statucka, Batu Kaya, Taylor W. Schmitz, Anthony C. Ruocco, Melanie Cohn   +6 more
wiley   +1 more source

A case of marked improvement in pareidolia in untreated schizophrenia following antipsychotic treatment. [PDF]

PCN Rep
Kato T, Seki E, Kumasaka T, Tsujii T, Mochizuki D, Kida H, Nikkuni S, Mizuno M, Sakuma K.   +8 more
europepmc   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Structural alteration of neurons in schizophrenia and its relation with auditory hallucination. [PDF]

Eur Psychiatry
Mizutani R, Saiga R, Yamamoto Y, Inomoto C, Kajiwara H, Kakimoto Y, Yasutake M, Uesugi M, Takeuchi A, Uesugi K, Terada Y, Suzuki Y, Nikitin V, De Carlo F, Torii Y, Kushima I, Ozaki N, Iritani S, Arai M, Oshima KI, Itokawa M.   +20 more
europepmc   +1 more source

Biológiai, kognitív és pszichopatológiai jellemzők szkizofréniában, hangulatzavarokban és egyes gyermekpszichiátriai kórképekben [PDF]

, 2017
Tényi, Tamás
core  

Psychiatric Comorbidity, Tic Severity and Quality of Life in Adults with Tourette's Syndrome

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Psychiatric comorbidities are common in adults with Tourette's Syndrome (TS), and appear to influence both tic severity and quality of life (QOL). Objective To assess the association between psychiatric comorbidities, tic severity and QOL in TS.
Andreas Hartmann, Christelle Nilles, Yulia Worbe, Davide Martino, Naoual Serari, Catherine Deans, Isabella Davenport, Julian Fletcher, Emmanuel Roze, Tamara Pringsheim   +9 more
wiley   +1 more source

A transcriptomic dimension of neuronal and immune gene programs within the subgenual anterior cingulate cortex in schizophrenia. [PDF]

Transl Psychiatry
Smith RL, Mihalik A, Akula N, Auluck PK, Marenco S, Raznahan A, Vértes PE, McMahon FJ.   +7 more
europepmc   +1 more source